1. Levinson, W. Review of Medical Microbiology and Immunology. 13th edition.
McGraw-Hill Education / Medical; 2014.
2. David Male, J. B., David Roth, Ivan Roitt, Immuno.logy, Eighth edition. Elsevier: 2012.
3. U.S. Department of Health and Human services, “Autoimmune diseases.”
(https://www.womenshealth.gov/a-z-topics/autoimmune-diseases, accessed as of May 3,
2021).
4. Yamanaka, H.; Sugiyama, N.; Inoue, E.; Taniguchi, A.; Momohara, S., Estimates of the
prevalence of and current treatment practices for rheumatoid arthritis in Japan using
reimbursement data from health insurance societies and the IORRA cohort (I). Mod
Rheumatol 2014, 24, 33-40.
5. Kubota, K.; Kamijima, Y.; Sato, T.; Ooba, N.; Koide, D.; Iizuka, H.; Nakagawa, H.,
Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the
Japanese national claims database. BMJ open 2015, 5, e006450.
6. Li, P.; Zheng, Y.; Chen, X., Drugs for Autoimmune Inflammatory Diseases: From Small
Molecule Compounds to Anti-TNF Biologics. Front Pharmacol. 2017, 8, 460-460.
7. Langrish, C. L.; Chen, Y.; Blumenschein, W. M.; Mattson, J.; Basham, B.; Sedgwick, J.
D.; McClanahan, T.; Kastelein, R. A.; Cua, D. J., IL-23 drives a pathogenic T cell
population that induces autoimmune inflammation. J. Exp. Med. 2005, 201, 233-40.
8. Yao, Z.; Fanslow, W. C.; Seldin, M. F.; Rousseau, A. M.; Painter, S. L.; Comeau, M. R.;
Cohen, J. I.; Spriggs, M. K., Herpesvirus Saimiri encodes a new cytokine, IL-17, which
binds to a novel cytokine receptor. Immunity 1995, 3, 811-21.
9. Roeleveld, D. M.; van Nieuwenhuijze, A. E.; van den Berg, W. B.; Koenders, M. I., The
Th17 pathway as a therapeutic target in rheumatoid arthritis and other autoimmune and
inflammatory disorders. BioDrugs. 2013, 27, 439-52.
10. Miossec, P.; Kolls, J. K., Targeting IL-17 and TH17 cells in chronic inflammation. Nat.
Rev. Drug Discov. 2012, 11, 763-76.
11. Beringer, A.; Noack, M.; Miossec, P., IL-17 in Chronic Inflammation: From Discovery to
Targeting. Trends Mol Med 2016, 22, 230-241.
12. Wilke, C. M.; Bishop, K.; Fox, D.; Zou, W., Deciphering the role of Th17 cells in human
disease. Trends Immunol. 2011, 32, 603-11.
13. Harcken, C.; Csengery, J.; Turner, M.; Wu, L.; Liang, S.; Sibley, R.; Brunette, S.; Labadia,
M.; Hoyt, K.; Wayne, A.; Wieckowski, T.; Davis, G.; Panzenbeck, M.; Souza, D.; Kugler,
S.; Terenzio, D.; Collin, D.; Smith, D.; Fryer, R. M.; Tseng, Y.-C.; Hehn, J. P.; Fletcher,
K.; Hughes, R. O., Discovery of a Series of Pyrazinone RORγ Antagonists and
98
Identification of the Clinical Candidate BI 730357. ACS Med. Chem. Lett. 2021, 12,
143-154.
14. Nakae, S.; Nambu, A.; Sudo, K.; Iwakura, Y., Suppression of Immune Induction of
Collagen-Induced Arthritis in IL-17-Deficient Mice. J. Immunol. 2003, 171, 6173-6177.
15. Langley, R. G.; Elewski, B. E.; Lebwohl, M.; Reich, K.; Griffiths, C. E.; Papp, K.; Puig,
L.; Nakagawa, H.; Spelman, L.; Sigurgeirsson, B.; Rivas, E.; Tsai, T. F.; Wasel, N.; Tyring,
S.; Salko, T.; Hampele, I.; Notter, M.; Karpov, A.; Helou, S.; Papavassilis, C.,
Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014, 371,
326-38.
16. Callis Duffin, K.; Bagel, J.; Bukhalo, M.; Mercado Clement, I. J.; Choi, S. L.; Zhao, F.;
Gill, A.; Pangallo, B.; Shuler, C.; Mallbris, L.; Jackson, K., Phase 3, open-label,
randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following
subcutaneous administration using a prefilled syringe or an autoinjector in patients with
moderate-to-severe plaque psoriasis (UNCOVER-A). J. Eur. Acad. Dermatol. Venereol.
2017, 31, 107-113.
17. Papp, K. A.; Reich, K.; Paul, C.; Blauvelt, A.; Baran, W.; Bolduc, C.; Toth, D.; Langley, R.
G.; Cather, J.; Gottlieb, A. B.; Thaçi, D.; Krueger, J. G.; Russell, C. B.; Milmont, C. E.; Li,
J.; Klekotka, P. A.; Kricorian, G.; Nirula, A., A prospective phase III, randomized,
double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe
plaque psoriasis. Br. J. Dermatol. 2016, 175, 273-86.
18. 日本皮膚科学会乾癬性関節炎診療ガイドライン作成委員会. “乾癬性関節炎診療ガ
イドライン 2019”
(https://www.dermatol.or.jp/uploads/uploads/files/guideline/PsAgl2019.pdf, accessed as
of May 3, 2021).
19. Eberl, G., RORγt, a multitask nuclear receptor at mucosal surfaces. Mucosal Immunol.
2017, 10, 27-34.
20. Giguere, V.; Tini, M.; Flock, G.; Ong, E.; Evans, R. M.; Otulakowski, G., Isoform-specific
amino-terminal domains dictate DNA-binding properties of ROR alpha, a novel family of
orphan hormone nuclear receptors. Genes. Dev. 1994, 8, 538-553.
21. Hirose, T.; Smith, R. J.; Jetten, A. M., ROR-γ: The Third Member of ROR/RZR Orphan
Receptor Subfamily That Is Highly Expressed in Skeletal Muscle. Biochem. Biophys. Res.
Commun. 1994, 205, 1976-1983.
22. He, Y.-W.; Deftos, M. L.; Ojala, E. W.; Bevan, M. J., RORγt, a novel isoform of an orphan
receptor, negatively regulates Fas ligand expression and IL-2 production in T cells.
Immunity 1998, 9, 797-806.
99
23. Jetten, A. M.; Takeda, Y.; Slominski, A.; Kang, H. S., Retinoic acid-related Orphan
Receptor γ (RORγ): connecting sterol metabolism to regulation of the immune system and
autoimmune disease. Curr Opin Toxicol 2018, 8, 66-80.
24. Ivanov, II; McKenzie, B. S.; Zhou, L.; Tadokoro, C. E.; Lepelley, A.; Lafaille, J. J.; Cua,
D. J.; Littman, D. R., The orphan nuclear receptor RORgammat directs the differentiation
program of proinflammatory IL-17+ T helper cells. Cell 2006, 126, 1121-33.
25. Yang, X. O.; Pappu, B. P.; Nurieva, R.; Akimzhanov, A.; Kang, H. S.; Chung, Y.; Ma, L.;
Shah, B.; Panopoulos, A. D.; Schluns, K. S.; Watowich, S. S.; Tian, Q.; Jetten, A. M.;
Dong, C., T helper 17 lineage differentiation is programmed by orphan nuclear receptors
ROR alpha and ROR gamma. Immunity 2008, 28, 29-39.
26. Jetten, A. M., Retinoid-related orphan receptors (RORs): critical roles in development,
immunity, circadian rhythm, and cellular metabolism. Nucl Recept Signal 2009, 7, e003.
27. 髙野光功 (2020). リード化合物の最適化を志向した、FAAH 阻害薬および RORγt
逆作動薬の分子設計と合成に関する研究. 慶應義塾大学大学院薬学研究科博士論
文.
28. UniProt Consortium , “UniProtKB - P51449 (RORG_HUMAN).”
(https://www.uniprot.org/uniprot/P51449, accessed as of May 4, 2021).
29. Fauber, B. P.; Magnuson, S., Modulators of the nuclear receptor retinoic acid
receptor-related orphan receptor-γ (RORγ or RORc). J. Med. Chem. 2014, 57, 5871-92.
30. Zhang, Y.; Luo, X.-y.; Wu, D.-h.; Xu, Y., ROR nuclear receptors: structures, related
diseases, and drug discovery. Acta Pharmacologica Sinica 2015, 36, 71-87.
31. Slominski, A. T.; Kim, T. K.; Takeda, Y.; Janjetovic, Z.; Brozyna, A. A.; Skobowiat, C.;
Wang, J.; Postlethwaite, A.; Li, W.; Tuckey, R. C.; Jetten, A. M., RORα and ROR γ are
expressed in human skin and serve as receptors for endogenously produced noncalcemic
20-hydroxy- and 20,23-dihydroxyvitamin D. FASEB J. 2014, 28, 2775-89.
32. Berg, K. A.; Clarke, W. P., Making Sense of Pharmacology: Inverse Agonism and
Functional Selectivity. Int. J. Neuropsychopharmacol.2018, 21, 962-977.
33. Khilnani, G.; Khilnani, A. K., Inverse agonism and its therapeutic significance. Indian J.
Pharmacol. 2011, 43, 492-501.
34. Wang, Y.; Kumar, N.; Solt, L. A.; Richardson, T. I.; Helvering, L. M.; Crumbley, C.;
Garcia-Ordonez, R. D.; Stayrook, K. R.; Zhang, X.; Novick, S.; Chalmers, M. J.; Griffin,
P. R.; Burris, T. P., Modulation of retinoic acid receptor-related orphan receptor alpha and
gamma activity by 7-oxygenated sterol ligands. J. Biol. Chem. 2010, 285, 5013-5025.
35. Jin, L.; Martynowski, D.; Zheng, S.; Wada, T.; Xie, W.; Li, Y., Structural Basis for
Hydroxycholesterols as Natural Ligands of Orphan Nuclear Receptor RORγ. Mol
Endocrinol 2010, 24, 923-929.
100
36. Soroosh, P.; Wu, J.; Xue, X.; Song, J.; Sutton, S. W.; Sablad, M.; Yu, J.; Nelen, M. I.; Liu,
X.; Castro, G.; Luna, R.; Crawford, S.; Banie, H.; Dandridge, R. A.; Deng, X.; Bittner, A.;
Kuei, C.; Tootoonchi, M.; Rozenkrants, N.; Herman, K.; Gao, J.; Yang, X. V.; Sachen, K.;
Ngo, K.; Fung-Leung, W.-P.; Nguyen, S.; de Leon-Tabaldo, A.; Blevitt, J.; Zhang, Y.;
Cummings, M. D.; Rao, T.; Mani, N. S.; Liu, C.; McKinnon, M.; Milla, M. E.; Fourie, A.
M.; Sun, S., Oxysterols are agonist ligands of RORγt and drive Th17 cell differentiation.
Proc. Natl. Acad. Sci. USA 2014, 111, 12163-12168.
37. Jetten, A. M.; Cook, D. N., (Inverse) Agonists of Retinoic Acid-Related Orphan Receptor
γ: Regulation of Immune Responses, Inflammation, and Autoimmune Disease. Annu Rev
Pharmacol Toxicol 2020, 60, 371-390.
38. Fujita-Sato, S.; Ito, S.; Isobe, T.; Ohyama, T.; Wakabayashi, K.; Morishita, K.; Ando, O.;
Isono, F., Structural basis of digoxin that antagonizes RORγt receptor activity and
suppresses Th17 cell differentiation and interleukin (IL)-17 production. J. Biol. Chem
2011, 286, 31409-31417.
39. Li, X.; Anderson, M.; Collin, D.; Muegge, I.; Wan, J.; Brennan, D.; Kugler, S.; Terenzio,
D.; Kennedy, C.; Lin, S.; Labadia, M. E.; Cook, B.; Hughes, R.; Farrow, N. A., Structural
studies unravel the active conformation of apo RORγt nuclear receptor and a common
inverse agonism of two diverse classes of RORγt inhibitors. J. Biol. Chem 2017, 292,
11618-11630.
40. Sun, N.; Xie, Q.; Dang, Y.; Wang, Y., Agonist Lock Touched and Untouched Retinoic Acid
Receptor-Related Orphan Receptor-γt (RORγt) Inverse Agonists: Classification Based on
the Molecular Mechanisms of Action. J. Med. Chem., 2021, 64, 10519-10536.
41. Solt, L. A.; Kumar, N.; Nuhant, P.; Wang, Y.; Lauer, J. L.; Liu, J.; Istrate, M. A.;
Kamenecka, T. M.; Roush, W. R.; Vidović, D.; Schürer, S. C.; Xu, J.; Wagoner, G.; Drew,
P. D.; Griffin, P. R.; Burris, T. P., Suppression of TH17 differentiation and autoimmunity
by a synthetic ROR ligand. Nature 2011, 472, 491-494.
42. Huh, J. R.; Leung, M. W.; Huang, P.; Ryan, D. A.; Krout, M. R.; Malapaka, R. R.; Chow,
J.; Manel, N.; Ciofani, M.; Kim, S. V., Digoxin and its derivatives suppress TH 17 cell
differentiation by antagonizing RORγt activity. Nature 2011, 472, 486-490.
43. Cherney, R. J.; Cornelius, L. A. M.; Srivastava, A.; Weigelt, C. A.; Marcoux, D.; Duan, J.
J. W.; Shi, Q.; Batt, D. G.; Liu, Q.; Yip, S.; Wu, D.-R.; Ruzanov, M.; Sack, J.; Khan, J.;
Wang, J.; Yarde, M.; Cvijic, M. E.; Mathur, A.; Li, S.; Shuster, D.; Khandelwal, P.;
Borowski, V.; Xie, J.; Obermeier, M.; Fura, A.; Stefanski, K.; Cornelius, G.; Tino, J. A.;
Macor, J. E.; Salter-Cid, L.; Denton, R.; Zhao, Q.; Carter, P. H.; Dhar, T. G. M., Discovery
of BMS-986251: A Clinically Viable, Potent, and Selective RORγt Inverse Agonist. ACS
Med. Chem. Lett. 2020, 11, 1221-1227.
101
44. Nishiyama, Y.; Nakamura, M.; Misawa, T.; Nakagomi, M.; Makishima, M.; Ishikawa, M.;
Hashimoto, Y., Structure-activity relationship-guided development of retinoic acid
receptor-related orphan receptor gamma (RORγ)-selective inverse agonists with a
phenanthridin-6(5H)-one skeleton from a liver X receptor ligand. Bioorg. Med. Chem.
2014, 22, 2799-808.
45. Toyama, H.; Nakamura, M.; Hashimoto, Y.; Fujii, S., Design and synthesis of novel ROR
inverse agonists with a dibenzosilole scaffold as a hydrophobic core structure. Bioorg.
Med. Chem. 2015, 23, 2982-2988.
46. Hirata, K.; Kotoku, M.; Seki, N.; Maeba, T.; Maeda, K.; Hirashima, S.; Sakai, T.; Obika,
S.; Hori, A.; Hase, Y.; Yamaguchi, T.; Katsuda, Y.; Hata, T.; Miyagawa, N.; Arita, K.;
Nomura, Y.; Asahina, K.; Aratsu, Y.; Kamada, M.; Adachi, T.; Noguchi, M.; Doi, S.;
Crowe, P.; Bradley, E.; Steensma, R.; Tao, H.; Fenn, M.; Babine, R.; Li, X.; Thacher, S.;
Hashimoto, H.; Shiozaki, M., SAR Exploration Guided by LE and Fsp3: Discovery of a
Selective and Orally Efficacious RORγ Inhibitor. ACS Med. Chem. Lett. 2016, 7, 23-27.
47. Sirois, L. E.; Lao, D.; Xu, J.; Angelaud, R.; Tso, J.; Scott, B.; Chakravarty, P.; Malhotra,
S.; Gosselin, F., Process Development Overcomes a Challenging Pd-Catalyzed C–N
Coupling for the Synthesis of RORc Inhibitor GDC-0022. Org. Process Res. Dev. 2020,
24, 567-578.
48. Xue, X.; Soroosh, P.; De Leon-Tabaldo, A.; Luna-Roman, R.; Sablad, M.; Rozenkrants,
N.; Yu, J.; Castro, G.; Banie, H.; Fung-Leung, W.-P.; Santamaria-Babi, L.; Schlueter, T.;
Albers, M.; Leonard, K.; Budelsky, A. L.; Fourie, A. M., Pharmacologic modulation of
RORγt translates to efficacy in preclinical and translational models of psoriasis and
inflammatory arthritis. Sci. Rep 2016, 6, 37977.
49. Kono, M.; Ochida, A.; Oda, T.; Imada, T.; Banno, Y.; Taya, N.; Masada, S.; Kawamoto, T.;
Yonemori, K.; Nara, Y.; Fukase, Y.; Yukawa, T.; Tokuhara, H.; Skene, R.; Sang, B.-C.;
Hoffman, I. D.; Snell, G. P.; Uga, K.; Shibata, A.; Igaki, K.; Nakamura, Y.; Nakagawa, H.;
Tsuchimori, N.; Yamasaki, M.; Shirai, J.; Yamamoto, S., Discovery of
[cis-3-({(5R)-5-[(7-Fluoro-1,1-dimethyl-2,3-dihydro-1H-inden-5-yl)carbamoyl]-2-methox
y-7,8-dihydro-1,6-naphthyridin-6(5H)-yl}carbonyl)cyclobutyl]acetic Acid (TAK-828F) as
a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan
Receptor γt Inverse Agonist. J. Med. Chem. 2018, 61, 2973-2988.
50. Huang, Y.; Yu, M.; Sun, N.; Tang, T.; Yu, F.; Song, X.; Xie, Q.; Fu, W.; Shao, L.; Wang, Y.,
Discovery of carbazole carboxamides as novel RORγt inverse agonists. Eur. J. Med. Chem.
2018, 148, 465-476.
51. Nakajima, R.; Oono, H.; Sugiyama, S.; Matsueda, Y.; Ida, T.; Kakuda, S.; Hirata, J.; Baba,
A.; Makino, A.; Matsuyama, R.; White, R. D.; Wurz, R. Ρ.; Shin, Y.; Min, X.;
Guzman-Perez, A.; Wang, Z.; Symons, A.; Singh, S. K.; Mothe, S. R.; Belyakov, S.;
102
Chakrabarti, A.; Shuto, S., Discovery of [1,2,4]Triazolo[1,5-a]pyridine Derivatives as
Potent and Orally Bioavailable RORγt Inverse Agonists. ACS Med. Chem. Lett. 2020, 11,
528-534.
52. Xu, T.; Wang, X.; Zhong, B.; Nurieva, R. I.; Ding, S.; Dong, C., Ursolic Acid Suppresses
Interleukin-17 (IL-17) Production by Selectively Antagonizing the Function of RORγt
Protein. J. Biol. Chem. 2011, 286, 22707-22710.
53. Bronner, S. M.; Zbieg, J. R.; Crawford, J. J., RORγ antagonists and inverse agonists: a
patent review. Expert Opin. Ther. Pat. 2017, 27, 101-112.
54. Xiao, S.; Yosef, N.; Yang, J.; Wang, Y.; Zhou, L.; Zhu, C.; Wu, C.; Baloglu, E.; Schmidt,
D.; Ramesh, R., Small-molecule RORγt antagonists inhibit T helper 17 cell transcriptional
network by divergent mechanisms. Immunity 2014, 40, 477-489.
55. Banerjee, D.; Zhao, L.; Wu, L.; Palanichamy, A.; Ergun, A.; Peng, L.; Quigley, C.;
Hamann, S.; Dunstan, R.; Cullen, P.; Allaire, N.; Guertin, K.; Wang, T.; Chao, J.; Loh, C.;
Fontenot, J. D., Small molecule mediated inhibition of RORγ-dependent gene expression
and autoimmune disease pathology in vivo. Immunology 2016, 147, 399-413.
56. Wang, Y.; Cai, W.; Cheng, Y.; Yang, T.; Liu, Q.; Zhang, G.; Meng, Q.; Han, F.; Huang, Y.;
Zhou, L.; Xiang, Z.; Zhao, Y.-G.; Xu, Y.; Cheng, Z.; Lu, S.; Wu, Q.; Xiang, J.-N.; Elliott, J.
D.; Leung, S.; Ren, F.; Lin, X., Discovery of Biaryl Amides as Potent, Orally Bioavailable,
and CNS Penetrant RORγt Inhibitors. ACS Med.Chem. Lett. 2015, 6, 787-792.
57. Gege, C., RORγt inhibitors as potential back-ups for the phase II candidate VTP-43742
from Vitae Pharmaceuticals: patent evaluation of WO2016061160 and US20160122345.
Expert Opin. Ther. Pat. 2017, 27, 1-8.
58. Takaishi, M.; Ishizaki, M.; Suzuki, K.; Isobe, T.; Shimozato, T.; Sano, S., Oral
administration of a novel RORγt antagonist attenuates psoriasis-like skin lesion of two
independent mouse models through neutralization of IL-17. J. Dermatol. Sci. 2017, 85,
12-19.
59. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J., Experimental and
computational approaches to estimate solubility and permeability in drug discovery and
development settings. Adv. Drug Deliv. Rev. 1997, 23, 3-25.
60. Bohl, C. E.; Gao, W.; Miller, D. D.; Bell, C. E.; Dalton, J. T., Structural basis for
antagonism and resistance of bicalutamide in prostate cancer. Proc. Natl. Acad. Sci. USA
2005, 102, 6201-6.
61. Yamamoto, S.; Tomita, N.; Suzuki, Y.; Suzaki, T.; Kaku, T.; Hara, T.; Yamaoka, M.;
Kanzaki, N.; Hasuoka, A.; Baba, A.; Ito, M., Design, synthesis, and biological evaluation
of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel
androgen receptor antagonists. Bioorg. Med. Chem. 2012, 20, 2338-2352.
103
62. Waring, M. J., Lipophilicity in drug discovery. Expert Opin. Drug Discov. 2010, 5,
235-48.
63. Jung, M. E.; Piizzi, G., gem-Disubstituent Effect: Theoretical Basis and Synthetic
Applications. Chem. Rev. 2005, 105, 1735-1766.
64. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D.,
Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. J. Med.
Chem. 2002, 45, 2615-2623.
65. Nassar, A.-E. F.; Kamel, A. M.; Clarimont, C., Improving the decision-making process in
the structural modification of drug candidates: enhancing metabolic stability. Drug Discov.
Today 2004, 9, 1020-1028.
66. Di, L.; Kerns, E. H., Drug-like properties: concepts, structure design and methods from
ADME to toxicity optimization. Academic press: 2015.
67. Fang, Z.; Song, Y.; Zhan, P.; Zhang, Q.; Liu, X., Conformational restriction: an effective
tactic in 'follow-on'-based drug discovery. Future Med. Chem. 2014, 6, 885-901.
68. Loughlin, W. A.; Tyndall, J. D. A.; Glenn, M. P.; Hill, T. A.; Fairlie, D. P., Update 1 of:
Beta-Strand Mimetics. Chem. Rev. 2010, 110, PR32-PR69.
69. Whitby, L. R.; Ando, Y.; Setola, V.; Vogt, P. K.; Roth, B. L.; Boger, D. L., Design,
Synthesis, and Validation of a b-Turn Mimetic Library Targeting Protein–Protein and
Peptide–Receptor Interactions. J. Am. Chem. Soc. 2011, 133, 10184-10194.
70. Cox, C. D.; McGaughey, G. B.; Bogusky, M. J.; Whitman, D. B.; Ball, R. G.; Winrow, C.
J.; Renger, J. J.; Coleman, P. J., Conformational analysis of
N,N-disubstituted-1,4-diazepane orexin receptor antagonists and implications for receptor
binding. Bioorg. Med. Chem. Lett. 2009, 19, 2997-3001.
71. Coleman, P. J.; Schreier, J. D.; Cox, C. D.; Breslin, M. J.; Whitman, D. B.; Bogusky, M.
J.; McGaughey, G. B.; Bednar, R. A.; Lemaire, W.; Doran, S. M., Discovery of [(2R,
5R)‐5‐{[(5‐Fluoropyridin‐2‐yl) oxy] methyl}‐2‐methylpiperidin‐1‐yl][5‐
methyl‐2‐(pyrimidin‐2‐yl) phenyl] methanone (MK‐6096): A Dual Orexin
Receptor Antagonist with Potent Sleep‐Promoting Properties. ChemMedChem 2012, 7,
415-424.
72. Fukumoto, S.; Ujikawa, O.; Morimoto, S.; Asano, Y.; Mikami, S.; Tokunaga, N.; Kori, M.;
Imaeda, T.; Fukuda, K.; Nakamura, S., Sulfonamide derivative and use thereof.
WO2012137982A2.
73. Shirai, J.; Tomata, Y.; Kono, M.; Ochida, A.; Fukase, Y.; Sato, A.; Masada, S.; Kawamoto,
T.; Yonemori, K.; Koyama, R.; Nakagawa, H.; Nakayama, M.; Uga, K.; Shibata, A.; Koga,
K.; Okui, T.; Shirasaki, M.; Skene, R.; Sang, B.; Hoffman, I.; Lane, W.; Fujitani, Y.;
Yamasaki, M.; Yamamoto, S., Discovery of orally efficacious RORγt inverse agonists,
104
part 1: Identification of novel phenylglycinamides as lead scaffolds. Bioorg. Med. Chem.
2018, 26, 483-500.
74. Brameld, K. A.; Kuhn, B.; Reuter, D. C.; Stahl, M., Small molecule conformational
preferences derived from crystal structure data. A medicinal chemistry focused analysis. J.
Chem. Inf. Model. 2008, 48, 1-24.
75. Schärfer, C.; Schulz-Gasch, T.; Ehrlich, H. C.; Guba, W.; Rarey, M.; Stahl, M., Torsion
angle preferences in druglike chemical space: a comprehensive guide. J. Med. Chem. 2013,
56, 2016-28.
76. Peglion, J.-L.; Goument, B.; Despaux, N.; Charlot, V.; Giraud, H.; Nisole, C.;
Newman-Tancredi, A.; Dekeyne, A.; Bertrand, M.; Genissel, P.; Millan, M. J.,
Improvement in the Selectivity and Metabolic Stability of the Serotonin 5-HT1A Ligand,
S 15535: A Series of cis- and trans-2-(Arylcycloalkylamine) 1-Indanols. J. Med. Chem.
2002, 45, 165-176.
77. Zhang, Q.; Ma, P.; Wang, W.; Cole, R. B.; Wang, G., In vitro metabolism of
diarylpyrazoles, a novel group of cannabinoid receptor ligands. Drug Metab. Dispos. 2005,
33, 508-517.
78. Nakagawa, H.; Koyama, R.; Kamada, Y.; Ochida, A.; Kono, M.; Shirai, J.; Yamamoto, S.;
Ambrus-Aikelin, G.; Sang, B. C.; Nakayama, M., Biochemical Properties of TAK-828F, a
Potent and Selective Retinoid-Related Orphan Receptor γt Inverse Agonist. Pharmacology
2018, 102, 244-252.
79. Otwinowski, Z.; Minor, W., Processing of X-ray diffraction data collected in oscillation
mode. Methods Enzymol. 1997, 276, 307-326.
80. Vagin, A.; Teplyakov, A., MOLREP: an Automated Program for Molecular Replacement.
J. Appl. Crystallogr. 1997, 30, 1022-1025.
81. McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read,
R. J., Phaser crystallographic software. J. Appl. Crystallogr. 2007, 40, 658-674.
82. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J., Refinement of macromolecular structures
by the maximum-likelihood method. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997,
53, 240-55.
83. McRee, D. E., XtalView/Xfit—A Versatile Program for Manipulating Atomic Coordinates
and Electron Density. J. Struct. Biol 1999, 125, 156-165.
84. Hoelke, B.; Gieringer, S.; Arlt, M.; Saal, C., Comparison of Nephelometric,
UV-Spectroscopic, and HPLC Methods for High-Throughput Determination of Aqueous
Drug Solubility in Microtiter Plates. Anal. Chem. 2009, 81, 3165-3172.
105
85. 小村, 弘.; 河原, 亥.; 茂本, 友.; 松田, 健.; 阿野, 理.; 村山, 洋.; 森脇, 俊.; 吉田,
長., 創薬における探索薬物動態スクリーニング（I）幅広い物性を有する化合物の
ための吸収評価系の確立. 薬学雑誌 2005, 125, 121-130.
86. Nakashima, S.; Yamamoto, K.; Arai, Y.; Ikeda, Y., Impact of Physicochemical Profiling
for Rational Approach on Drug Discovery. Chem. Pharm. Bull. 2013, 61, 1228-1238.
106
発表論文一覧 [主論文]
1. Identification of novel quinazolinedione derivatives as RORγt inverse agonist.
Fukase, Y.; Sato, A.; Tomata, Y.; Ochida, A.; Kono, M.; Yonemori, K.; Koga, K.; Okui, T.;
Yamasaki, M.; Fujitani, Y.; Nakagawa, H.; Koyama, R.; Nakayama, M.; Skene, R.; Sang,
B.-C.; Hoffman, I.; Shirai, J.; Yamamoto, S. Bioorg. Med. Chem. 2018, 26, 721-736.
2. Design and Synthesis of Conformationally Constrained RORγt Inverse Agonists.
Sato, A.; Fukase, Y.; Kono, M.; Ochida, A.; Oda, T.; Sasaki, Y.; Ishii, N.; Tomata, Y.;
Fukumoto, S.; Imai, Y. N.; Uga, K.; Shibata, A.; Yamasaki, M.; Nakagawa, H.; Shirasaki,
M.; Skene, R.; Hoffman, I.; Sang, B.-C.; Snell, G.; Shirai, J.; Yamamoto, S.,
ChemMedChem 2019, 14, 1917-1932.
107
謝辞
本論文の発表および作成にあたり、終始ご懇切なるご指導とご鞭撻を賜りました
東京大学大学院薬学系研究科 内山真伸 教授に謹んで御礼申し上げます。また、本
論文の審査にあたり、ご指導ならびにご助言を賜りました東京大学大学院薬学系研究
科 金井求 教授、平野圭一 特任准教授、長友優典 講師、生長幸之助 講師に厚
く御礼申し上げます。
本研究は武田薬品工業株式会社医薬研究本部で行われたものであり、本研究に際し
て、御協力、御助言いただきました池浦義典博士、一川隆史博士、神山圭司博士、
吉田雅都博士、伊井雅幸博士に心より感謝いたします。
本研究を通じ、終始温かいご指導、ご助言ならびにご援助を賜りました山本哲史
博士、白井淳也氏、深瀬嘉之博士、遠又慶英博士、落田温子博士、髙野光功博士、
小田恒夫氏、佐々木悠介博士、石井直樹氏、福本正司博士、今井友美博士、米森和子
氏、中川秀行氏、小山亮吉氏、中山政治氏、宇賀恵子氏、柴田央博士、古賀敬子博士、
奥井利豪氏、土森登博士、山嵜将司博士、藤谷靖志博士、白崎幹雄氏、Robert Skene
氏、Bi-Ching Sang 氏、Isaac Hoffman 氏、Gyorgy Snell 博士に深く感謝いたします。
本研究の成果は、多くの共同研究者の方々のご協力とご尽力の賜物であり、ここに
心より深く感謝いたします。また、本研究にご協力いただいたすべての方に感謝いた
します。
本論文を執筆する上で、有益なご助言をいただきました Axcelead Drug Discovery
Partners 株式会社 北村周治博士、伊藤光博博士に深く感謝いたします。
学部、大学院において研究者としての基本をご指導いただき、本論文執筆のきっか
けを与えて下さった東京大学名誉教授 福山透 教授に心より御礼申し上げます。
最後に、いつも支えてくれた家族に心より感謝いたします。
108
...
論文の公開元へ
